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Understanding nitric oxide (NO) in innate anti-viral immunity and immune-mediated pathology is
hampered by incomplete details of its transcriptional and signaling factors. We found in macro-
phages that IRF3, ERK MAP-kinases, and PKR are essential to NO production in response to RNA-
virus mimic, poly I:C, a TLR3 agonist. ERK’s role in NO induction may be through phosphorylation
of serine-171 of IRF3 and expression of NO-inducing cytokines, IL-6 and IFN-b. However, these cyto-
kines induced less NO in IRF3 knockout or knockdown macrophages. These ﬁndings show that ERK
and IRF3 coordinate induction of NO by macrophages in response to stimulation of TLR3.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Nitric oxide (NO) production by macrophages plays an impor-
tant role in innate immunity and disease progression. NO can con-
tribute to host defense by limiting viral infections [1,2] but also
contribute to lung pathology during inﬂuenza virus infection [3].
Additionally, NO is an important component of central nervous
system disorders such as Alzheimer’s disease, multiple sclerosis,
and amyotropic lateral sclerosis [4,5]. Therefore, an understanding
of signaling pathways that contribute to NO production is impor-
tant for both the study and treatment of numerous human
diseases.
Toll-like receptors (TLRs) recognize pathogen associate molec-
ular patterns and induce signal transduction pathways that lead
to activation of immune responses [6]. In particular, TLR3 recog-
nizes double stranded RNA (dsRNA) and the dsRNA analog, polyI:C, and induces expression of antiviral genes and secretion of
reactive oxygen species such as NO [1,7]. Recognition of poly
I:C by TLR3 recruits the adapter toll/IL-1R (TIR) domain-contain-
ing adaptor-inducing IFN-b (TRIF) and activates the kinases
TBK1 and IKKe, which phosphorylate the C-terminus of interferon
regulatory factor 3 (IRF3) [7,8], leading to its activation, and
expression of cytokines such as IFN-b [9] or IL-6 [10]. However,
poly I:C also leads to activation of non-canonical kinases such
as mitogen activated protein kinases (MAPKs) [11,12]. Interest-
ingly, early studies on IRF3 activation pointed to its phosphoryla-
tion by MAPKs such as JNK and p38 [13–15]. It remains unclear in
which contexts, if any, MAPK phosphorylation could lead to IRF3
activation.
In this study, we found that extracellular signal related kinase
(ERK) MAPK inhibitor, U0126, protein kinase R (PKR) inhibitor,
2-aminopurine, and phosphoinositide-3-kinase (PI3K) inhibitor,
LY294002, all reduced NO induced by poly I:C in the mouse macro-
phage cell line, RAW264.7, and primary mouse macrophages. In
addition, U0126 inhibited poly I:C-induced IFN-b, IL-6, and iNOS
expression as well as induction of NO downstream of these cyto-
kines. Furthermore, data showing ERK phosphorylation of IRF3
and decreased IL-6- or IFN-p-induced NO in IRF3 knockout or
knockdown macrophages suggest that activation of IRF3 contrib-
utes to IL-6-induced NO. Therefore, both poly I:C-induced IFN-b
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Fig. 1. ERK is involved in poly I:C-induced nitric oxide production in macrophages. (A) RAW264.7 cells were untreated (no inhib) or pretreated with U0126, SP600125, 2-
aminopurine (2-amino), SB203580, LY294002, or PKC inhibitor for 30 min and then treated with 50 lg/ml poly I:C for 24 h or left untreated (control). (B, C) B10.s peritoneal
macrophages (B) or RAW264.7 cells (C) were pre-treated with U0126 and then treated with 50 lg/ml poly I:C (B) or 10 lg/ml LPS (C), or transfected with ERK MAPK speciﬁc
ODNs or scrambled control ODNs and then stimulated with 50 lg/ml LPS (D) for 24 h or left untreated (control). The supernatant was removed and nitric oxide was analyzed
by Greiss assay. Data are means ± S.E.M. of 4–6 samples per group.
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IFN-b could depend on ERK phosphorylation of IRF3.
2. Materials and methods
2.1. Mice, cell lines, and reagents
B10.s mice were offspring of breeder pairs generously provided
by Dr. Michel Brahic (Stanford University). IRF3 deﬁcient mice
(IRF3KO) on the C57BL/6 (BL/6) background were offspring of bree-
der pairs obtained from Dr. Karen Mossman (McMaster University)
[16]. OT-II mice on a BL/6 background were used as IRF3+/+ mice
and were obtained from Jackson Labs, (Bar Harbor, ME).
RAW264.7 cells were obtained from the American Type Culture
Collection (Rockville, MD) and maintained in culture media
(DMEM with 10% FBS with 50 lg/ml gentamycin). For stable selec-
tion of shRNAs, RAW264.7 cells were transfected with 2 lg psh-
IRF3 or psh-Control (psiRNA vector, Invivogen) with the Amaxa
nucleofector. Stable lines were selected with 100 lg/ml Zeocin.
Knockdown was conﬁrmed by Western blot and qRT-PCR (data
not shown). For transient knockdown of ERK MAPKs, 2 lM
phosphorothioate-oligonucleotides (ODNs) that target ERK 1 and
2 (50-GCCGCCGCCGCCGCCAT-30) or scrambled ODNs (50-CGCGCG
CTCGCGCACCC-30) were transfected into RAW264.7 cells with the
Amaxa nucleofector as previously described [17]. Escherichia coli
lipopolysaccharide (LPS)O127:B8 was obtained from Sigma Chem-
ical Co. (St. Louis, MO), and poly I:C from InvivoGen (San Diego,
CA). The p38 MAPK inhibitor SB203580 (10 lM), Myristoylated
PKC inhibitor (400 lM), PI3K inhibitor LY294002 (50 lM), and
ERK MAPK inhibitor U0126 (40 lM) were from Promega Corpora-
tion (Madison, WI). The JNK MAPK inhibitor SP600126 (44 lM)
was from Biosource (Camarillo, CA) and the PKR inhibitor 2-amino-
purine (5 mM) from InvivoGen.2.2. Macrophage preparations
Peritoneal macrophages were elicited by i.p. injection of 2 ml
sterile thioglycollate broth into mice. Three days later, the perito-
neal cavities were ﬂushed with 2 ml DMEM and cells were incu-
bated at 1  106 cells/2 ml culture media. After overnight
incubation, non-adherent cells were removed and 1 ml of culture
medium added. Adherent cells were greater than 90% Mac-1 + as
determined by FACS analysis [18]. These macrophages were either
untreated or treated as described in the ﬁgure legends.
2.3. ERK kinase assay
40 lg of IRF3-S171 peptide (DEGSSDLAIVSDPSQQLPSPNVN
NFLNPAP) or IRF3-S135 peptide (GASPDTNGKSSLPHSQENLPKL
FDGLILGP), or no peptide (synthesized from Thermo scientiﬁc/
Fisher) was added to kinase buffer (40 mM Tris, 20 mM MgCl2,
0.1 mg/ml BSA) containing 770 lM ATP, and 250 ng active ERK1
(Signal Chem, Richmond, BC, Canada) or no ERK. The kinase reac-
tion was allowed to proceed at room temperature for 40 min and
phosphorylation was detected using the kinase detection kit from
Promega.
2.4. RNA preparations and qRT-PCR
RNA was extracted from cells using the Purelink kit from Ambi-
on/Invitrogen (Carlsbad, CA), according to the manufacturer’s spec-
iﬁcations. One hundred nanograms to 1 lg of RNA was reverse
transcribed in .5 mM each of dATP, dGTP, dTTP, and dCTP, 20 U of
RNAse inhibitor with Superscript II reverse transcriptase (Invitro-
gen) at 42 C for 1.5 h followed by 95 C for 5 min. The cDNA was
diluted 1:2 and 1 ll was incubated with .4 mM of the following
primer pairs (Invitrogen): IFN-b sense 50-ATGAACAACAG
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Fig. 2. ERK is involved in poly I:C-induced IFN-b and IL-6 expression. (A, B) RAW264.7 cells were untreated or pretreated with U0126 for 30 min and then treated with 50 lg/
ml poly I:C for 6 or 24 h. RNA was collected from cell lysates, reverse transcribed, and IFN-b (A), IL-6 (B) and iNOS (C) expression was analyzed by qRT-PCR. Data are
means ± S.E.M. of 3–4 samples per group.
3016 T.C. Moore, T.M. Petro / FEBS Letters 587 (2013) 3014–3020GTGGATCCTCC-30 and anti-sense 50-AGGAGCTCCTGACATTTCC-
GAA-30; IL-6 sense 50-ATGAAGTTCCT CTCTGCAAGAGACT-30 and
antisense 50-CACTAGGTTTGCC GAGTAGATCTC-30; iNOS sense 50-
CCCTTCCGAAGTTTCTGGCAGCAGC and anti-sense 50-GGCTGCA-
GAGCCTCGTGCTTTGG-30; or GAPDH sense 50-TTGTCAGCAA
TGCATCCTGCAC-30; and antisense 50-ACAGCTTTCCA GAGGGGC-
CATC-30. Quantitative (q) PCR reactions were run on an ABI Prism
7000 thermal cycler at 50 C for 2 min, 95 C for 10 min, 45 cycles
of 95 C for 15 s/60 C for 30 s. Relative levels of mRNA were nor-
malized to GAPDH by using the Ct value and the formula: 2DDCt.
2.5. Statistical analysis
Statistical analyses were performed using GraphPad Prism Soft-
ware. Student’s two-tailed unpaired t test was used to determine
the signiﬁcance of differences between means; ⁄P < .05, ⁄⁄P < .01,
⁄⁄⁄P < .001, ⁄⁄⁄⁄P < .0001.
3. Results
3.1. ERK is involved in the induction of NO in response to poly I:C and
LPS in macrophages
Viral RNA, and the dsRNA analog, poly I:C, signal through TLR3
and adapter TRIF to induce NO [1,19]. Although the TLR3/TRIF sig-
naling cascade has been well studied, pathways that lead to poly
I:C-induced NO production are not well understood. In order toreveal kinases that contribute to NO production during stimula-
tion with dsRNA, RAW264.7 macrophages were pretreated with
well-characterized speciﬁc inhibitors of ERK MAPK (U0126), JNK
MAPK (SP600125), PKR (2-aminopurine), p38 MAPK (SB203580),
PI3K (LY294002), or PKC for 30 min at previously optimized con-
centrations and then stimulated with 50 lg/ml poly I:C for 24 h.
Supernatants were then analyzed for NO secretion by way of Gre-
iss assay. As shown in Fig. 1 A, poly I:C stimulated NO production
in RAW264.7 macrophages. NO production was inhibited by
U0126, 2-aminopurine, and LY294002, which indicate that ERK
MAPK, PKR, and PI3K, respectively, are involved in poly I:C-in-
duced NO. Because previous reports showed that PKR is involved
in poly I:C-induced NO [19] and LY294002 blocks poly I:C-in-
duced IRF3 activation [20], we decided to focus our subsequent
studies on ERK MAPK. Consistent with our observations in
RAW264.7 macrophages, the induction of NO in poly I:C-treated
primary macrophages from B10.s mice was also ERK dependent
(Fig. 1B). In order to further investigate a role for ERK MAPK in
NO induction, these experiments were repeated using LPS, which
signals through TLR4 in either a TRIF dependent or TRIF-indepen-
dent manor [21], activates MAPKs [13], and is also a potent indu-
cer of NO [22]. LPS-stimulated NO production from RAW264.7
cells was signiﬁcantly inhibited by U0126 (Fig. 1C) or by anti-
sense ODN transient knockdown of ERK MAPKs (Fig. 1D). Taken
together, these results show that ERK MAPK is a critical signaling
molecule for the induction of NO in macrophages responding to
either poly I:C or LPS.
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Fig. 3. ERK is involved in nitric oxide production downstream of IFN-p and IL-6. (A) RAW264.7 cells were pre-treated with no inhibitor (no inhib), U0126, SP600125 or 2-
aminopurine (2-amino) for 30 min and then treated with 10 lg/ml IFN-b for 24 h or left untreated (control). (B, C) B10.s peritoneal macrophages (B) or RAW264.7 cells (C)
were pre-treated with U0126 and then treated with 10 lg/ml IFN-b (B) or 10 lg/ml IL- 6 (C) for 24 h or left untreated (control). The supernatant was removed and nitric oxide
was analyzed by Greiss assay. Data are means ± S.E.M. of 3–4 samples per group.
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I:C-treated macrophages
Previously, we found that ERK MAPK was required for maxi-
mum expression of IL-6 by macrophages infected with Theiler’s
virus, which is recognized, in part, by TLR3 [23,24]. Moreover, we
showed that IL-6 was able to synergistically enhance NO in Theil-
er’s virus infected macrophages [2]. Because of these data and the
fact that poly I:C induces IFN-b, a potent inducer of NO [25], we
determined if reduced NO in U0126-pretreated macrophages could
be due to decreased expression of IL-6 or IFN-b. Indeed, U0126 pre-
treatment signiﬁcantly inhibited induction of both IFN-b (Fig. 2A)
and IL-6 (Fig. 2B) in response to poly I:C. As expected, the reduction
of poly I:C-induced IFN-b and IL-6 expression by U0126 pretreat-
ment correlated with decreased expression of inducible nitric
oxide synthase (iNOS) at 24 h. Therefore, the role of ERK in poly
I:C-induced NO is partly at the level of transcription of cytokines,
such as IFN-b and IL-6, and the induction of iNOS expression.
3.3. ERK is involved in induction of NO downstream of lFN-b and IL-6
Although inhibiting ERK activity signiﬁcantly reduced expres-
sion of IFN-b and IL-6 in response to poly I:C, ERK could also medi-
ate NO production downstream of IFN-b and IL-6. In order to test
whether ERK is involved in production of NO downstream of IFN-
b and IL-6, RAW264.7 macrophages were pretreated with U0126,
SP600125, or 2-aminopurine and then treated with IFN-b for
24 h. Interestingly, both U0126 and 2-aminopurine signiﬁcantly
reduced induction of NO by IFN-b (Fig. 3A). U0126 also signiﬁ-
cantly reduced IFN-b-induced NO in primary macrophages fromB10.s mice (Fig. 3B) and inhibited IL-6-induced NO production
from RAW264.7 cells (Fig. 3C). These and the aforementioned re-
sults show that in addition to its involvement in poly I:C-induced
IFN-b and IL-6 expression, ERK is involved in signaling downstream
of IFN-b and IL-6 during NO induction.
3.4. Role of IRF3 in ERK-mediated NO induction
Recently, we found that IRF3 is involved in expression of both
IFN-b and IL-6 from macrophages in response to Theiler’s virus,
as well as poly I:C (Moore et al., under review). Also, we found that
IRF3 is critical for induction of interferon stimulated genes and IL-
6-induced antiviral effects. Because both ERK and IRF3 are required
for maximum IFN-b and IL-6 expression, as well as some of their
downstream effects, we tested whether ERK could potentially acti-
vate IRF3 through phosphorylation. Using Scansite 3.0 software
[26] to analyze the mouse IRF3 protein sequence, we identiﬁed a
putative ERK kinase target at serine 171 (S171) of mouse IRF3.
Importantly, alignment of human and mouse IRF3 with Clustal
Omega from the European Bioinformatics Institute (EBI) revealed
that this serine is conserved with human IRF3 (Fig. 4A) [27]. In or-
der to test whether ERK could phosphorylate IRF3, we mixed puri-
ﬁed activated ERK with 30-mer peptides that contain the putative
ERK S171 site of IRF3 or with peptides that contain a conﬁrmed
DNA-protein kinase site of IRF3 at S135 [28]. In vitro kinase assays
revealed a signiﬁcant increase in kinase-dependent phosphoryla-
tion of the S171 peptide (Fig. 4B). In contrast, kinase dependent
phosphorylation with the S135 peptides was equivalent to control,
and can therefore be attributed to ERK autophosphorylation. Inac-
tive ERK, used as a negative control, yielded no signiﬁcant kinase
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Fig. 4. Role of IRF3 in poly I:C and IFN-p-induced NO. (A) Mouse and Human IRF3 were aligned using the Clustal Omega software from EBI. (B) ERK phosphorylation of S135,
S172, or no peptide control solutions was performed as described in the materials and methods. (C) RAW264.7 stably expressing shIRF3 or control shRNA were infected with 2
MOI Theiler’s virus with or without 10 lg/ml IL-6. (D) Peritoneal macrophages from IRF3+/+ or IRF3/ mice were pre-treated with U0126 (D) or no inhibitor (D) and then
treated with 50 lg/ml poly I:C (D), infected with Theiler’s virus (E), or treated with 10 lg/ml IFN-b (F) for 24 h. The supernatant was removed and nitric oxide was analyzed by
Greiss assay (D, F) or RNA was extracted for analysis of iNOS expression by qRT-PCR. Data are means ± S.E.M. of 3–4 samples per group.
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potential target of ERK dependent phosphorylation at IRF3 S171
but not IRF3 S135.
To test if IRF3 is required for induction of NO in response to poly
I:C, we compared poly-I:C-induced NO from RAW264.7 cells with
shRNA plasmids that knocked down IRF3 expression. The IRF3
targeted shRNA prevented production of NO in response to IL-6
(Fig. 4C). We also compared poly-I:C-induced NO from IRF3+/+
macrophages on a Bl6 background with that from IRF3 deﬁcient
(IRF3/) macrophages on a Bl6 background. Similar to
RAW264.7 cells and B10.S macrophages, poly I:C induced signiﬁ-
cant NO production after 24 h treatment of IRF3+/+ macrophages
(Fig. 4D). In contrast, IRF3 deﬁcient (IRF3/) macrophages did
not produce NO in response to poly I:C (Fig. 4D). This lack of NO
production in IRF3/ macrophages also correlated with a lack ofiNOS induction (Fig. 4E). These results show that IRF3 is critical
to induction of NO in macrophages responding to poly I:C or IL6.
To test whether IRF3 and ERK are involved in NO production in
macrophages downstream of IFN-b, IRF3+/+ or IRF3/ macro-
phages were pretreated with U0126 and then treated with 10 ng/
ml IFN-p for 24 h. In contrast to poly I:C, IFN-p induced some NO
from IRF3/ macrophages, albeit to a signiﬁcantly lesser degree
than from IRF3+/+ macrophages (Fig. 4F). Moreover, pretreatment
with ERK inhibitor U0126 reduced NO in both IRF3+/+ and IRF3/
macrophages (Fig. 4F). Taken together, these results suggest that
ERK phosphorylation of IRF3 contributes to NO production both
through induction of IFN-b and IL-6 and also in signaling pathways
downstream of these cytokines. However, other ERK targets in
addition to IRF3 appear to be important inducers of NO down-
stream of IFN-b.
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Previously we showed that IL-6 is able to induce robust NO pro-
duction from the RAW264.7 macrophage cell line [1,2]. The data in
this report demonstrate that poly I:C, an agonist of the TLR3 pat-
tern recognition receptor, also induces NO production from
RAW264.7 cells. Furthermore, we show that ERK MAPK is involved
in NO production by macrophages responding to poly I:C. ERK ap-
pears to contribute to NO production, in part, by promoting expres-
sion of NO-inducing cytokines such as IFN-b and IL-6, but is also
involved in NO induction in response to these cytokines and in
iNOS expression.
Herein the data also indicate that IRF3 is critical for poly I:C-in-
duced NO production. This is consistent with our previous report
which shows that IRF3 is involved in IL-6 and IFN-b expression dur-
ing Theiler’s virus infection of macrophages (Moore et al, under re-
view). Surprisingly, in this report, we found that IRF3 is required for
maximum induction of NO in response to exogenous IFN-b or IL-6.
These data are similar to our previous ﬁndings in which IRF3 deﬁ-
ciency impaired IL-6 induction of interferon stimulated genes and
impaired STAT1 phosphorylation in response to IL-6. Taken to-
gether, this suggests that IFN-b and IL-6 can signal, in part, in an
IRF3-dependent manor. Herein, we suggest ERK as a possible link
between the IFN-b or IL-6 receptors and IRF3. However, IFN-b-in-
ducedNOwas still inhibited byU0126 in IRF3/macrophages, sug-
gesting that IRF3 is only one of the targets for ERK downstream of
IFN-b. Although these studies suggest that IRF3 is involved in ampli-
fyingNO inducedby cytokines, further studies are required to deﬁne
the mechanism of IRF3 involvement downstream of IFN-b and IL-6.
In addition to ERK, our results suggest that PKR and PI3K are
other cell signaling factors associated with poly I:C-induced NO.
The latter is consistent with a previous report showing that poly
I:C-induced NO in astrocytes depends on PKR-mediated activation
of nuclear factor j-B (NF-jB). However, LY294002 has recently
been shown to inhibit poly I:C-induced IRF3 activation by an un-
known, PI3K-independent mechanism [29]. Therefore, it is possible
that LY294002 reduces NO production by macrophages through
inhibition of IRF3 activity directly and not through inhibition of
PI3K activity.
Several early reports suggested that MAPKs are involved in IRF3
activation. In particular, both p38 MAPK and JNK MAPK have been
shown to activate IRF3 [13,14]. However, our results indicate that
lack of IRF3, but not inhibition of p38 or JNK, abolishes poly I:C-in-
duced NO. Our results further implicate ERK in the activation of
IRF3 that leads to production of NO by macrophages. A recent re-
port showed that during cardiac ﬁbrosis, angiotensin II promotes
IRF3 activation by way of ERK phosphorylation [30]. In this system,
they found that S339 of IRF3 to be the critical ERK phosphorylation
site. Our results show that ERK phosphorylation of IRF3 at S171
may be an additional ERK phosphorylation target on IRF3.
In conclusion, these results show that poly I:C stimulation of
macrophages induces NO in an ERK and IRF3-dependent manor
that may involve ERK phosphorylation of IRF3. This is important
because of the wide array of human diseases that are mitigated
or exaggerated by NO production. This study, in conjunction with
future studies, will provide insight into signaling pathways that
promote NO production and may contribute to the development
of treatments for NO-mediated diseases.
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